BioDynamics Research Foundation, Japan
Dr. Hiroshi Maeda, M.D., Ph.D., Professor Emeritus of Kumamoto University is a world renowned expert in macromolecular therapeutics. He was successful in creating the world first polymeric drug, SMANCS (1979), which was approved for treatment of hepatoma in Japan in 1993. Along this line he discovered the concept of EPR (enhanced permeability and retention) effect of macromolecular drugs, a ubiquitous mechanism, which is responsible for solid tumor selective drug-targeting of polymeric drugs. More recently, he has developed a numbers of macromolecular/micellar drugs with very high tumor selective accumulation. This concept is also applicable to micellar and liposomal drugs, gene complexed nanoparticles, and even oncolytic virus particles. He received his Master’s Degree from the University of California at Davis, where he was a Fulbright Fellow, and his Ph.D. and M.D. from Tohoku University in Sendai, Japan. He has had more than 500 papers published in international reputed journals. He received the Princess Takamatsu Award in Cancer Research, Dr. Tomizo Yoshida Award, the highest award from Japan Cancer Association in 2011, and many other awards from various societies in USA, Germany, UK and Japan. He is an awardee of the 2016 Thomson Reuter Web of Science Citation Laureates in Chemistry division, top 3 in the world. Maeda’s paper in Cancer Research (1986) on the discovery of EPR effect is the most cited original article in that journal out of about 100,000 article (by AACR, Dr. Foti). He is an honorary mayer of San Antonio, Texas, and honorary citizen of Oklahoma State of USA.